Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

18.8%

3 terminated/withdrawn out of 16 trials

Success Rate

70.0%

-16.5% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

9(56.3%)

Phase 2

6(37.5%)

Phase 3

1(6.3%)

16Total

Phase 1(9)

Phase 2(6)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT06637865Phase 1Recruiting

A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers

Role: lead

NCT03625323Phase 2Completed

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Role: lead

NCT06726265Phase 3Active Not Recruiting

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Role: lead

NCT07102940Phase 2Not Yet Recruiting

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

Role: collaborator

NCT03252938Phase 1Active Not Recruiting

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Role: collaborator

NCT04811027Phase 2Completed

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Role: lead

NCT06128863Phase 2Active Not Recruiting

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

Role: collaborator

NCT05747794Phase 2Active Not Recruiting

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

Role: lead

NCT04252768Phase 1Withdrawn

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

Role: lead

NCT02614833Phase 2Completed

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

Role: lead

NCT01308294Phase 1Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients

Role: collaborator

NCT00365937Phase 1Terminated

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Role: collaborator

NCT00349934Phase 1Completed

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma